QBiotics appoints Jefferies and Bell Potter as Joint Lead Managers

2 weeks ago

Brisbane, Queensland, Australia QBiotics Group Full time
QBiotics appoints Jefferies and Bell Potter as Joint Lead Managers

BRISBANE, 25 March 2025

QBiotics Group Limited (QBiotics) is pleased to announce it has appointed Jefferies (Australia) Pty Ltd (Jefferies) and Bell Potter Securities Limited (Bell Potter) as Joint Lead Managers (JLMs) to advise upon and assist QBiotics with a potential initial public offering (IPO) on the Australian Securities Exchange (ASX) this calendar year.

QBiotics Non-Executive Chairman, Mark Fladrich commented, "We are pleased to be taking the next step toward a potential ASX listing. This reflects the dedication of our entire team, and I want to acknowledge our co-founders, Dr Victoria Gordon and Dr Paul Reddell for their vision and leadership. Their contributions have been instrumental in bringing us to this stage."

QBiotics CEO and Managing Director, Stephen Doyle commented, "The appointment of Jefferies and Bell Potter as Joint Lead Managers is a sign of our commitment to move towards a potential ASX listing. Jefferies and Bell Potter bring deep healthcare expertise, strong institutional relationships and a global investor network. We are pleased to be working closely together on this process."

Shareholders should note the appointment of JLMs (or any other professional advisors) does not guarantee that an IPO will proceed. Any decision including the timing of the IPO will be made in due course, subject to market conditions and other relevant factors.

The Company remains committed to keeping shareholders informed as developments arise.

QBiotics is an unlisted public Australian life sciences company specialising in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.

QBiotics' lead oncology drug, tigilanol tiglate is currently in human clinical Phase II trials in Soft Tissue Sarcoma and Head and Neck Cancer. Tigilanol tiglate has received Orphan Drug Designation from the US FDA for the treatment of Soft Tissue Sarcomas. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA , in the USA, Europe, the UK and Australia.

QBiotics' lead wound healing drug candidate, EBC 1013, is a small molecule targeting a range of wounds including chronic and acute wounds and burns. A first-in-human Phase I clinical development in patients with venous leg ulcers is open for recruitment.

#J-18808-Ljbffr

  • QBiotics appoints Jefferies and Bell Potter as Joint Lead Managers

    3 weeks ago

    Brisbane, Queensland, Australia QBiotics Group Full time

    QBiotics appoints Jefferies and Bell Potter as Joint Lead ManagersBRISBANE, 25 March 2025QBiotics Group Limited (QBiotics) is pleased to announce it has appointed Jefferies (Australia) Pty Ltd (Jefferies) and Bell Potter Securities Limited (Bell Potter) as Joint Lead Managers (JLMs) to advise upon and assist QBiotics with a potential initial public offering...

  • Qbiotics Appoints Jefferies And Bell Potter As Joint Lead Managers

    1 week ago

    Brisbane, Queensland, Australia Qbiotics Group Full time

    QBiotics appoints Jefferies and Bell Potter as Joint Lead ManagersBRISBANE, 25 March 2025QBiotics Group Limited (QBiotics) is pleased to announce it has appointed Jefferies (Australia) Pty Ltd (Jefferies) and Bell Potter Securities Limited (Bell Potter) as Joint Lead Managers (JLMs) to advise upon and assist QBiotics with a potential initial public offering...

  • Strategic Advisory Role

    3 days ago

    Brisbane, Queensland, Australia beBeeLeadership Full time $150,000 - $200,000

    Appointment of Joint Lead ManagersWe are seeking a seasoned professional to join our advisory team as Joint Lead Manager. This strategic appointment will enable us to leverage the expertise of Jefferies and Bell Potter in advising on a potential initial public offering (IPO) on the Australian Securities Exchange.This esteemed role reflects our dedication to...

  • QBiotics leadership transition

    2 weeks ago

    Brisbane, Queensland, Australia QBiotics Group Full time

    OverviewAs part of its leadership transition, the Board of QBiotics is pleased to announce the following changes with effect from 22 October 2024.Sue Foden returns to the role of Non-Executive Chair of the BoardCEO Stephen Doyle appointed to the Board of Directors as Managing DirectorCo-founder, Victoria Gordon retires from QBiotics' executive team while...

  • QBiotics leadership transition

    2 weeks ago

    Brisbane, Queensland, Australia QBiotics Group Full time

    OverviewAs part of its leadership transition, the Board of QBiotics is pleased to announce the following changes with effect from 22 October 2024.- Sue Foden returns to the role of Non-Executive Chair of the Board- CEO Stephen Doyle appointed to the Board of Directors as Managing Director- Co-founder, Victoria Gordon retires from QBiotics' executive team...

  • Qbiotics Leadership Transition

    1 week ago

    Brisbane, Queensland, Australia Qbiotics Group Full time

    OverviewAs part of its leadership transition, the Board of QBiotics is pleased to announce the following changes with effect from 22 October 2024.Sue Foden returns to the role of Non-Executive Chair of the BoardCEO Stephen Doyle appointed to the Board of Directors as Managing DirectorCo-founder, Victoria Gordon retires from QBiotics' executive team while...

  • Catalyst Appointment

    6 days ago

    Brisbane, Queensland, Australia beBeeExpertise Full time $200,000 - $250,000

    Job OpportunityWe are pleased to announce the appointment of a joint team of lead managers to advise upon and assist with a potential initial public offering (IPO) on the Australian Securities Exchange.This reflects the dedication of our entire team, acknowledging the contributions of our co-founders, Dr Victoria Gordon and Dr Paul Reddell.The appointed...

  • Strategic Healthcare Expert

    2 weeks ago

    Brisbane, Queensland, Australia beBeeHealthcare Full time $2,000,000 - $2,500,000

    Job DescriptionQBiotics is seeking a Lead Manager to advise on and assist with a potential initial public offering (IPO) on the Australian Securities Exchange (ASX). The successful candidate will be responsible for providing expertise in healthcare, institutional relationships, and global investor networks.This role involves strategic planning, guidance, and...

  • Assistant Manager Taco Bell

    1 week ago

    Brisbane, Queensland, Australia Collins Restaurants Management Full time $60,000 - $80,000 per year

    At Taco Bell, we feed people's lives with Más. We deliver Más Flavor, Más Heart and Más Value and this means we add more flavor to life and we do things differently.Taco Bell have always been trailblazers. It started back in '62 in Southern California, when our courageous Godfather Glen Bell, introduced the crunchy taco and forever revolutionised food...

  • Leadership Transition Professional

    2 days ago

    Brisbane, Queensland, Australia beBeeTransition Full time $100,000 - $150,000

    Job Title:Senior Leadership Transition ProfessionalJob Description:As part of its leadership transition, the Board is pleased to announce changes with effect from 22 October 2024.Sue Foden returns to the role of Non-Executive Chair of the BoardCEO Stephen Doyle appointed to the Board of Directors as Managing DirectorCo-founder Victoria Gordon retires from...